Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients
Science
Thoughtful exploration of new and validated pathways to discover and develop novel therapeutics
News
November 12,
2024
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12,
2024
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
October 10,
2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
Events
Monday,
September 9TH,
2024
at
7:00 AM
Eastern
H. C. Wainwright 26th Annual Global Investment Conference
Listen: Webcast
Thursday,
June 20TH,
2024
at
8:30 AM
Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]
Wednesday,
June 5TH,
2024
at
4:00 PM
Eastern
Jefferies Global Healthcare Conference
Listen: Webcast
Wednesday,
May 29TH,
2024
at
2:00 PM
Eastern
TD Cowen's 5th Annual Oncology Innovation Summit
Listen: Webcast
Wednesday,
October 11TH,
2023
at
8:30 AM
Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]